Sep 17, 2009 - APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. FDA to market Deferoxamine Mesylate for Injection, USP, in two dosage strengths.
The details can be read here.
No comments:
Post a Comment